Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12 - Seite 2
Pseudovirus and authentic virus studies demonstrate that the Therapy retains neutralization activity against the Delta (B.1.617.2/AY.3) variant, the currently predominant variant of concern worldwide.
According to the statistics from Lilly, over 700,000 patients have been treated with the Therapy or bamlanivimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths during the worst of the pandemic.
About Etesevimab (JS016/LY-CoV016)
Etesevimab is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block
the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from
the Company after it was jointly developed by the Company and the Institute of Microbiology, Chinese Academy of Science. The Company leads development in Greater China (including mainland China,
the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the Taiwan region), while Lilly leads development in the rest of the world. The Therapy has obtained EUA in
more than 15 countries and regions worldwide. The Company has completed a Phase Ib/II international multi-center clinical study (NCT04780321) of etesevimab for patients with mild to moderate
COVID-19. Results from a Phase 2/3 study sponsored by Lilly in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) were published in the New England Journal of Medicine.
Lesen Sie auch
About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of
innovative therapeutics. The company has established a diversified R & D pipeline comprising 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic,
neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its
first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first
in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli
Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use
Authorizations (EUA) in 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences
has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.